# Phase I/IIa Clinical Trial of IMC001 in Patients With Advanced Epithelial Solid Tumors.

> **NCT07644403** · PHASE1,PHASE2 · ENROLLING_BY_INVITATION · sponsor: **Suzhou Immunofoco Biotechnology Co., Ltd** · enrollment: 30 (estimated)

## Conditions studied

- Epithelial Cancer Patients

## Interventions

- **DRUG:** Autologous CAR-T cell injection targeting EpCAM

## Key facts

- **NCT ID:** NCT07644403
- **Lead sponsor:** Suzhou Immunofoco Biotechnology Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2026-03-05
- **Primary completion:** 2027-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-06-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07644403

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07644403, "Phase I/IIa Clinical Trial of IMC001 in Patients With Advanced Epithelial Solid Tumors.". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07644403. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*